WFNOS 2017
Clinical trials of VAL-083 in patients with chemoresistant glioblastoma
WFNOS 2017
Distinct mechanism of action of dianhydrogalactitol (VAL-083) overcomes chemoresistance in glioblastoma
AACR Annual Meeting 2017
Molecular Mechanisms of Dianhydrogalactitol (VAL-083) in Overcoming Chemoresistance in Glioblastoma
AACR Annual Meeting 2017
DNA damage response to dianhydrogalactitol (VAL-083) in p53-deficient non-small cell lung cancer cells
IASCL 17th World Congress on Lung Cancer
Assessment of Dianhydrogalactitol (VAL-083) in the Treatment of Relapsed or Refractory Non-Small Cell Lung Cancer
EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium
Molecular mechanisms of dianhydrogalactitol (VAL-083) in overcoming GBM chemo-resistance
Society for Neuro-Oncology
Molecular mechanisms of dianhydrogalactitol (VAL-083) in overcoming GBM chemo-resistance
Society for Neuro-Oncology
Clinical Trials of VAL-083 in Patients with Chemo-Resistant Glioblastoma
AACR New Horizons in Cancer Research
Assessment of dianhydrogalactitol (VAL-083) in the treatment of relapsed or refractory non-small cell lung cancer (NSCLC)
European Association for NeuroOncology Annual Meeting
Dianhydrogalactitol (VAL-083) causes irreparable DNA double-strand breaks, S/G2 phase cell-cycle arrest and tumor cell death in an MGMT independent manner offering a unique treatment paradigm for GBM